A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia
A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash...
Gespeichert in:
| Veröffentlicht in: | International clinical psychopharmacology 1990-04, Vol.5 Suppl 2, p.29 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 29 |
| container_title | International clinical psychopharmacology |
| container_volume | 5 Suppl 2 |
| creator | Fleming, J A McClure, D J Mayes, C Phillips, R Bourgouin, J |
| description | A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash-out period, followed by 4 placebo nights of withdrawal monitoring. During the investigation, a 17 item post-sleep questionnaire was completed daily, the Clinical Global Impression (CGI) scale weekly, and the Hamilton Anxiety Scale (HAM-A) at baseline and at the end of the study. Withdrawal effects were evaluated with a withdrawal symptom checklist and the CGI (withdrawal). Results indicated that both compounds improved sleep and were equally effective. However, a larger number of triazolam subjects withdrew from the study because of ineffectiveness or adverse side-effects. A greater number of zopiclone subjects experienced a transient modification of taste which disappeared with discontinuation of therapy. Significant deterioration in nearly all sleep parameters were noted after the first withdrawal night of triazolam; much fewer modifications of sleep parameters were observed following the discontinuation of zopiclone. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_2201728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201728</sourcerecordid><originalsourceid>FETCH-LOGICAL-p206t-658acb6e81ccf5078a3892ed9e7a314355c834295a3a4754fe289d7e1f6840403</originalsourceid><addsrcrecordid>eNotj8tqwzAURLVoSdO0n1DQB9Sgpy0vQ-gLAtm063AjXxEVSzKWSnC-vnWa1QzM4cDckCUTtam45PqO3Of8zZhgvFULshB_pRFmSfKa2hQGGH1OkSZHyxEpOuct2OmZZnBYJgqxoydfjt0IJ-jnHW3JM35Og7d9inhhyujhnHoI1MeLqYwIJWAsM-tjTiF6eCC3DvqMj9dcka_Xl8_Ne7XdvX1s1ttqEKwuVa0N2EONhlvrNGsMSNMK7FpsQHIltbZGKtFqkKAarRwK03YNclcbxRSTK_L07x1-DgG7_TD6AOO0v56Xv7THVes</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Fleming, J A ; McClure, D J ; Mayes, C ; Phillips, R ; Bourgouin, J</creator><creatorcontrib>Fleming, J A ; McClure, D J ; Mayes, C ; Phillips, R ; Bourgouin, J</creatorcontrib><description>A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash-out period, followed by 4 placebo nights of withdrawal monitoring. During the investigation, a 17 item post-sleep questionnaire was completed daily, the Clinical Global Impression (CGI) scale weekly, and the Hamilton Anxiety Scale (HAM-A) at baseline and at the end of the study. Withdrawal effects were evaluated with a withdrawal symptom checklist and the CGI (withdrawal). Results indicated that both compounds improved sleep and were equally effective. However, a larger number of triazolam subjects withdrew from the study because of ineffectiveness or adverse side-effects. A greater number of zopiclone subjects experienced a transient modification of taste which disappeared with discontinuation of therapy. Significant deterioration in nearly all sleep parameters were noted after the first withdrawal night of triazolam; much fewer modifications of sleep parameters were observed following the discontinuation of zopiclone.</description><identifier>ISSN: 0268-1315</identifier><identifier>PMID: 2201728</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Azabicyclo Compounds ; Double-Blind Method ; Female ; Humans ; Hypnotics and Sedatives ; Male ; Middle Aged ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Psychomotor Performance - drug effects ; Randomized Controlled Trials as Topic ; Sleep Initiation and Maintenance Disorders - drug therapy ; Sleep Stages - drug effects ; Substance Withdrawal Syndrome - etiology ; Triazolam - adverse effects ; Triazolam - therapeutic use ; Wakefulness - drug effects</subject><ispartof>International clinical psychopharmacology, 1990-04, Vol.5 Suppl 2, p.29</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2201728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleming, J A</creatorcontrib><creatorcontrib>McClure, D J</creatorcontrib><creatorcontrib>Mayes, C</creatorcontrib><creatorcontrib>Phillips, R</creatorcontrib><creatorcontrib>Bourgouin, J</creatorcontrib><title>A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia</title><title>International clinical psychopharmacology</title><addtitle>Int Clin Psychopharmacol</addtitle><description>A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash-out period, followed by 4 placebo nights of withdrawal monitoring. During the investigation, a 17 item post-sleep questionnaire was completed daily, the Clinical Global Impression (CGI) scale weekly, and the Hamilton Anxiety Scale (HAM-A) at baseline and at the end of the study. Withdrawal effects were evaluated with a withdrawal symptom checklist and the CGI (withdrawal). Results indicated that both compounds improved sleep and were equally effective. However, a larger number of triazolam subjects withdrew from the study because of ineffectiveness or adverse side-effects. A greater number of zopiclone subjects experienced a transient modification of taste which disappeared with discontinuation of therapy. Significant deterioration in nearly all sleep parameters were noted after the first withdrawal night of triazolam; much fewer modifications of sleep parameters were observed following the discontinuation of zopiclone.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Azabicyclo Compounds</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Hypnotics and Sedatives</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Psychomotor Performance - drug effects</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Sleep Initiation and Maintenance Disorders - drug therapy</subject><subject>Sleep Stages - drug effects</subject><subject>Substance Withdrawal Syndrome - etiology</subject><subject>Triazolam - adverse effects</subject><subject>Triazolam - therapeutic use</subject><subject>Wakefulness - drug effects</subject><issn>0268-1315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj8tqwzAURLVoSdO0n1DQB9Sgpy0vQ-gLAtm063AjXxEVSzKWSnC-vnWa1QzM4cDckCUTtam45PqO3Of8zZhgvFULshB_pRFmSfKa2hQGGH1OkSZHyxEpOuct2OmZZnBYJgqxoydfjt0IJ-jnHW3JM35Og7d9inhhyujhnHoI1MeLqYwIJWAsM-tjTiF6eCC3DvqMj9dcka_Xl8_Ne7XdvX1s1ttqEKwuVa0N2EONhlvrNGsMSNMK7FpsQHIltbZGKtFqkKAarRwK03YNclcbxRSTK_L07x1-DgG7_TD6AOO0v56Xv7THVes</recordid><startdate>19900401</startdate><enddate>19900401</enddate><creator>Fleming, J A</creator><creator>McClure, D J</creator><creator>Mayes, C</creator><creator>Phillips, R</creator><creator>Bourgouin, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19900401</creationdate><title>A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia</title><author>Fleming, J A ; McClure, D J ; Mayes, C ; Phillips, R ; Bourgouin, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p206t-658acb6e81ccf5078a3892ed9e7a314355c834295a3a4754fe289d7e1f6840403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Azabicyclo Compounds</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Hypnotics and Sedatives</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Psychomotor Performance - drug effects</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Sleep Initiation and Maintenance Disorders - drug therapy</topic><topic>Sleep Stages - drug effects</topic><topic>Substance Withdrawal Syndrome - etiology</topic><topic>Triazolam - adverse effects</topic><topic>Triazolam - therapeutic use</topic><topic>Wakefulness - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fleming, J A</creatorcontrib><creatorcontrib>McClure, D J</creatorcontrib><creatorcontrib>Mayes, C</creatorcontrib><creatorcontrib>Phillips, R</creatorcontrib><creatorcontrib>Bourgouin, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>International clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleming, J A</au><au>McClure, D J</au><au>Mayes, C</au><au>Phillips, R</au><au>Bourgouin, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia</atitle><jtitle>International clinical psychopharmacology</jtitle><addtitle>Int Clin Psychopharmacol</addtitle><date>1990-04-01</date><risdate>1990</risdate><volume>5 Suppl 2</volume><spage>29</spage><pages>29-</pages><issn>0268-1315</issn><abstract>A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash-out period, followed by 4 placebo nights of withdrawal monitoring. During the investigation, a 17 item post-sleep questionnaire was completed daily, the Clinical Global Impression (CGI) scale weekly, and the Hamilton Anxiety Scale (HAM-A) at baseline and at the end of the study. Withdrawal effects were evaluated with a withdrawal symptom checklist and the CGI (withdrawal). Results indicated that both compounds improved sleep and were equally effective. However, a larger number of triazolam subjects withdrew from the study because of ineffectiveness or adverse side-effects. A greater number of zopiclone subjects experienced a transient modification of taste which disappeared with discontinuation of therapy. Significant deterioration in nearly all sleep parameters were noted after the first withdrawal night of triazolam; much fewer modifications of sleep parameters were observed following the discontinuation of zopiclone.</abstract><cop>England</cop><pmid>2201728</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-1315 |
| ispartof | International clinical psychopharmacology, 1990-04, Vol.5 Suppl 2, p.29 |
| issn | 0268-1315 |
| language | eng |
| recordid | cdi_pubmed_primary_2201728 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Azabicyclo Compounds Double-Blind Method Female Humans Hypnotics and Sedatives Male Middle Aged Piperazines - adverse effects Piperazines - therapeutic use Psychomotor Performance - drug effects Randomized Controlled Trials as Topic Sleep Initiation and Maintenance Disorders - drug therapy Sleep Stages - drug effects Substance Withdrawal Syndrome - etiology Triazolam - adverse effects Triazolam - therapeutic use Wakefulness - drug effects |
| title | A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A20%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparison%20of%20the%20efficacy,%20safety%20and%20withdrawal%20effects%20of%20zopiclone%20and%20triazolam%20in%20the%20treatment%20of%20insomnia&rft.jtitle=International%20clinical%20psychopharmacology&rft.au=Fleming,%20J%20A&rft.date=1990-04-01&rft.volume=5%20Suppl%202&rft.spage=29&rft.pages=29-&rft.issn=0268-1315&rft_id=info:doi/&rft_dat=%3Cpubmed%3E2201728%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2201728&rfr_iscdi=true |